

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant J. Vernon Knight <i>et al.</i>	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
AS	A1	5,049,388	01/17/91	Knight <i>et al.</i>	424	450	07/21/89
	A2	5,422,344	06/06/95	Priel <i>et al.</i>	514	50	05/08/90
	A3	5,552,156	01/03/96	Burke	424	450	03/22/95
	A4	5,736,156	04/07/98	Burke	424	450	04/12/96
	A5	5,958,378	01/28/99	Waldrep <i>et al.</i>	424	45	10/16/96
	A6	6,090,407	07/18/00	Knight <i>et al.</i>	424	450	11/23/97
↓	A7	6,346,233	02/12/02	Knight <i>et al.</i>	424	45	07/17/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
AS	B1	DB 4430593C2	08/20/94	Germany	Abstract
	B2	WO 9318751	03/23/93	WIPO	English
	B3	WO 9426253	05/16/94	WIPO	English
	B4	WO 9605821	08/18/95	WIPO	Abstract
↓	B5	WO 9619199	12/20/95	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AS	C1	"Chiron submits new drug application for pulminiq; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection," www.drugs.com/nda/pulminiq_041014.html 9/14/06
AS	C2	Abang <i>et al.</i> , "The clinical pharmacology of topoisomerase I inhibitors," <i>Sem Hematol</i> , 35:13-21, 1998.

25693214.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPE609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)